Pharmaceutical policy in Pakistan

Muhammad Atif, Mahmood Ahmad, Quratulain Saleem, Louise Curley, Muhammad Qamar-Uz-Zaman, Zaheer Ud Din Babar

Research output: Chapter in Book/Report/Conference proceedingChapter

13 Citations (Scopus)

Abstract

Pakistan is a lower middle-income country, and healthcare in the country is regulated by the Ministry of National Health Services Regulation and Coordination. The overall poor performance in health care is reflected in the form of enormous burden of communicable and non-communicable diseases, and high maternal, neonatal and infant mortality rates. These issues are coupled with a reduced health sector investment and a lack of health insurance schemes. There is no pharmacovigilance system, and there are also problems with counterfeit medications. Nevertheless, Pakistan has a dynamic pharmaceutical sector ranking10th largest in the Asia-Pacific region and fulfilling 70% of the country’s medicinal demands. Many finished pharmaceutical products from Pakistan have been deemed acceptable by countries across Asia, Africa and the United States. Pharmaceutical regulation is governed by the Drug Regulatory Authority of Pakistan (DRAP) which ensures the implementation of the Drugs Act, 1976 (XXXI of 1976). Pakistan’s national essential medicine list (NEML) is based on the WHO standards and promotes generic prescribing; however, this list is generally only followed in the public sector hospitals. The majority of prescribers in the private sector health facilities are influenced by pharmaceutical marketing. There are concerns related to underuse and overuse of certain medicines reflecting an irrational medicines use in the country. There are also policy concerns related to drug pricing due to an absence of a sound medicine pricing formula. A full range of essential drugs is not available in public sector hospitals, either because of inadequate operational budget or due to lack of efficient management. Many consumers in Pakistan can buy medicines without prescription, leading to poor dispensing practices. However, despite numerous issues, the country has shown signs of improvement with regard to healthcare system. The Prime Minister’s National Health Insurance Program initiative, the establishment of drug testing laboratories and the strict punishments for the breach of laws related to medicines’ related offences are few examples that show that the government is serious to improve healthcare.

LanguageEnglish
Title of host publicationPharmaceutical Policy in Countries with Developing Healthcare Systems
PublisherSpringer International Publishing AG
Pages25-44
Number of pages20
ISBN (Electronic)9783319516738
ISBN (Print)9783319516721
DOIs
Publication statusPublished - 1 Jan 2017

Fingerprint

Drug and Narcotic Control
Pakistan
Pharmaceutical Preparations
National Health Programs
Delivery of Health Care
Public Sector
Public Hospitals
Infant Mortality
Essential Drugs
Pharmacovigilance
Costs and Cost Analysis
Punishment
Private Sector
Maternal Mortality
Health Facilities
Budgets
Health Insurance
Marketing
Prescriptions
Medicine

Cite this

Atif, M., Ahmad, M., Saleem, Q., Curley, L., Qamar-Uz-Zaman, M., & Babar, Z. U. D. (2017). Pharmaceutical policy in Pakistan. In Pharmaceutical Policy in Countries with Developing Healthcare Systems (pp. 25-44). Springer International Publishing AG. https://doi.org/10.1007/978-3-319-51673-8_3
Atif, Muhammad ; Ahmad, Mahmood ; Saleem, Quratulain ; Curley, Louise ; Qamar-Uz-Zaman, Muhammad ; Babar, Zaheer Ud Din. / Pharmaceutical policy in Pakistan. Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing AG, 2017. pp. 25-44
@inbook{eeb8b60fde5c4c64ad64ed2f9763fda4,
title = "Pharmaceutical policy in Pakistan",
abstract = "Pakistan is a lower middle-income country, and healthcare in the country is regulated by the Ministry of National Health Services Regulation and Coordination. The overall poor performance in health care is reflected in the form of enormous burden of communicable and non-communicable diseases, and high maternal, neonatal and infant mortality rates. These issues are coupled with a reduced health sector investment and a lack of health insurance schemes. There is no pharmacovigilance system, and there are also problems with counterfeit medications. Nevertheless, Pakistan has a dynamic pharmaceutical sector ranking10th largest in the Asia-Pacific region and fulfilling 70{\%} of the country’s medicinal demands. Many finished pharmaceutical products from Pakistan have been deemed acceptable by countries across Asia, Africa and the United States. Pharmaceutical regulation is governed by the Drug Regulatory Authority of Pakistan (DRAP) which ensures the implementation of the Drugs Act, 1976 (XXXI of 1976). Pakistan’s national essential medicine list (NEML) is based on the WHO standards and promotes generic prescribing; however, this list is generally only followed in the public sector hospitals. The majority of prescribers in the private sector health facilities are influenced by pharmaceutical marketing. There are concerns related to underuse and overuse of certain medicines reflecting an irrational medicines use in the country. There are also policy concerns related to drug pricing due to an absence of a sound medicine pricing formula. A full range of essential drugs is not available in public sector hospitals, either because of inadequate operational budget or due to lack of efficient management. Many consumers in Pakistan can buy medicines without prescription, leading to poor dispensing practices. However, despite numerous issues, the country has shown signs of improvement with regard to healthcare system. The Prime Minister’s National Health Insurance Program initiative, the establishment of drug testing laboratories and the strict punishments for the breach of laws related to medicines’ related offences are few examples that show that the government is serious to improve healthcare.",
author = "Muhammad Atif and Mahmood Ahmad and Quratulain Saleem and Louise Curley and Muhammad Qamar-Uz-Zaman and Babar, {Zaheer Ud Din}",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-51673-8_3",
language = "English",
isbn = "9783319516721",
pages = "25--44",
booktitle = "Pharmaceutical Policy in Countries with Developing Healthcare Systems",
publisher = "Springer International Publishing AG",
address = "Switzerland",

}

Atif, M, Ahmad, M, Saleem, Q, Curley, L, Qamar-Uz-Zaman, M & Babar, ZUD 2017, Pharmaceutical policy in Pakistan. in Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing AG, pp. 25-44. https://doi.org/10.1007/978-3-319-51673-8_3

Pharmaceutical policy in Pakistan. / Atif, Muhammad; Ahmad, Mahmood; Saleem, Quratulain; Curley, Louise; Qamar-Uz-Zaman, Muhammad; Babar, Zaheer Ud Din.

Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing AG, 2017. p. 25-44.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Pharmaceutical policy in Pakistan

AU - Atif, Muhammad

AU - Ahmad, Mahmood

AU - Saleem, Quratulain

AU - Curley, Louise

AU - Qamar-Uz-Zaman, Muhammad

AU - Babar, Zaheer Ud Din

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Pakistan is a lower middle-income country, and healthcare in the country is regulated by the Ministry of National Health Services Regulation and Coordination. The overall poor performance in health care is reflected in the form of enormous burden of communicable and non-communicable diseases, and high maternal, neonatal and infant mortality rates. These issues are coupled with a reduced health sector investment and a lack of health insurance schemes. There is no pharmacovigilance system, and there are also problems with counterfeit medications. Nevertheless, Pakistan has a dynamic pharmaceutical sector ranking10th largest in the Asia-Pacific region and fulfilling 70% of the country’s medicinal demands. Many finished pharmaceutical products from Pakistan have been deemed acceptable by countries across Asia, Africa and the United States. Pharmaceutical regulation is governed by the Drug Regulatory Authority of Pakistan (DRAP) which ensures the implementation of the Drugs Act, 1976 (XXXI of 1976). Pakistan’s national essential medicine list (NEML) is based on the WHO standards and promotes generic prescribing; however, this list is generally only followed in the public sector hospitals. The majority of prescribers in the private sector health facilities are influenced by pharmaceutical marketing. There are concerns related to underuse and overuse of certain medicines reflecting an irrational medicines use in the country. There are also policy concerns related to drug pricing due to an absence of a sound medicine pricing formula. A full range of essential drugs is not available in public sector hospitals, either because of inadequate operational budget or due to lack of efficient management. Many consumers in Pakistan can buy medicines without prescription, leading to poor dispensing practices. However, despite numerous issues, the country has shown signs of improvement with regard to healthcare system. The Prime Minister’s National Health Insurance Program initiative, the establishment of drug testing laboratories and the strict punishments for the breach of laws related to medicines’ related offences are few examples that show that the government is serious to improve healthcare.

AB - Pakistan is a lower middle-income country, and healthcare in the country is regulated by the Ministry of National Health Services Regulation and Coordination. The overall poor performance in health care is reflected in the form of enormous burden of communicable and non-communicable diseases, and high maternal, neonatal and infant mortality rates. These issues are coupled with a reduced health sector investment and a lack of health insurance schemes. There is no pharmacovigilance system, and there are also problems with counterfeit medications. Nevertheless, Pakistan has a dynamic pharmaceutical sector ranking10th largest in the Asia-Pacific region and fulfilling 70% of the country’s medicinal demands. Many finished pharmaceutical products from Pakistan have been deemed acceptable by countries across Asia, Africa and the United States. Pharmaceutical regulation is governed by the Drug Regulatory Authority of Pakistan (DRAP) which ensures the implementation of the Drugs Act, 1976 (XXXI of 1976). Pakistan’s national essential medicine list (NEML) is based on the WHO standards and promotes generic prescribing; however, this list is generally only followed in the public sector hospitals. The majority of prescribers in the private sector health facilities are influenced by pharmaceutical marketing. There are concerns related to underuse and overuse of certain medicines reflecting an irrational medicines use in the country. There are also policy concerns related to drug pricing due to an absence of a sound medicine pricing formula. A full range of essential drugs is not available in public sector hospitals, either because of inadequate operational budget or due to lack of efficient management. Many consumers in Pakistan can buy medicines without prescription, leading to poor dispensing practices. However, despite numerous issues, the country has shown signs of improvement with regard to healthcare system. The Prime Minister’s National Health Insurance Program initiative, the establishment of drug testing laboratories and the strict punishments for the breach of laws related to medicines’ related offences are few examples that show that the government is serious to improve healthcare.

UR - http://www.scopus.com/inward/record.url?scp=85030253084&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-51673-8_3

DO - 10.1007/978-3-319-51673-8_3

M3 - Chapter

SN - 9783319516721

SP - 25

EP - 44

BT - Pharmaceutical Policy in Countries with Developing Healthcare Systems

PB - Springer International Publishing AG

ER -

Atif M, Ahmad M, Saleem Q, Curley L, Qamar-Uz-Zaman M, Babar ZUD. Pharmaceutical policy in Pakistan. In Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing AG. 2017. p. 25-44 https://doi.org/10.1007/978-3-319-51673-8_3